• Shionogi posted FY2025 revenue of JPY 499.7 billion, up 14%, while operating profit rose 6.5% to JPY 166.7 billion.
• Profit before tax climbed 19% to JPY 238.9 billion, while profit attributable to owners of parent increased 20.4% to JPY 205.2 billion.
• Royalty income rose 13.9% to JPY 278.6 billion, including HIV franchise revenue up 8.7% to JPY 261.3 billion.
• FY2026 forecast calls for revenue of JPY 700 billion, up 40.1%, with operating profit seen at JPY 220 billion, up 32%.
• Completed equity acquisition in ViiV Healthcare, reclassifying ViiV as an equity-method affiliate on March 31, 2026, while transferring edaravone rights to Shionogi on April 1, 2026 and launching a new U.S. company for RADICAVA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.